Clinical Trials Logo

Clinical Trial Summary

OBJECTIVES: I. Determine whether allelic differences associated with the fourth component of complement, type-1 complement receptor expressed on erythrocytes, and Fc receptor FcgRIII contribute to the pathogenesis of IgA glomerulonephritis (IgA-N).

II. Compare genetic anomalies of these key components in immune complex processing and clearance between juvenile vs adult onset IgA-N vs normal controls.


Clinical Trial Description

PROTOCOL OUTLINE:

Participants undergo qualitative genetic analysis of complement-related proteins. Studies include: genomic re-arrangement of 4-gene unit, C4 DNA sequence and RNA expression, type-1 complement receptor DNA sequence, Fc-gamma receptor IIIA isoform analysis, classical and alternative complement activation pathway assays, plasma C4 and C4d protein levels, and immunoglobulin patterns in glomerular deposits. ;


Study Design

Primary Purpose: Screening


Related Conditions & MeSH terms


NCT number NCT00004305
Study type Observational
Source National Center for Research Resources (NCRR)
Contact
Status Completed
Phase N/A
Start date January 1998

See also
  Status Clinical Trial Phase
Completed NCT00004448 - Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy Phase 2
Completed NCT01560052 - Therapeutic Evaluation of Steroids in IgA Nephropathy Global Study (TESTING Low Dose Study) N/A
Completed NCT00006137 - Pilot Study of Enalapril and Renal Function in Patients With IgA Nephropathy N/A
Completed NCT02527902 - Autonomic Nervous System (ANS) and Renal Function in Immunoglobin A (IgA) Nephropathy N/A
Completed NCT01115426 - Inhibitors of Angiotensin II in Proteinuric Mesangioproliferative Glomerulonephritis Phase 4